OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Launched by AMGEN · Aug 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called olpasiran to see if it can help lower the risk of serious heart problems like heart attacks, death from heart disease, or emergency procedures to open blocked heart arteries. It is focused on people who have high levels of a substance in their blood called lipoprotein(a), or Lp(a), which can increase the chance of heart disease. The goal is to find out if olpasiran can prevent a first major heart event in people who have not yet had one but are at higher risk because of their Lp(a) levels and other heart-related risk factors.

To be eligible for this study, participants need to be 50 years or older, have high Lp(a) levels (200 nmol/L or above), and have several risk factors for heart disease or signs of artery problems. People who have already had major heart attacks, strokes, or certain artery procedures are not eligible. Participants will receive either olpasiran or a placebo (a treatment with no medicine) and will be closely monitored to see if the medicine helps reduce their risk of serious heart events. This study is currently recruiting volunteers, and anyone interested should talk to their doctor to see if they might qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥50 years
• • Lp(a)≥ 200 nmol/L during screening
• • Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
• Exclusion Criteria:
• • Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
• • Prior or planned arterial revascularization
• • History of major bleeding disorder